newsfilter
← Latest News
Business Wire·

Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program

Sage and Biogen will continue to partner on ZURZUVAE®, the first and only FDA-approved oral treatment for women with postpartum depression Sage Therapeutics, Inc. (NASDAQ:SAGE) today announced that Biogen has